CDK9 inhibitors push cancer cells over the edge

Matthew W Nowicki; Malcolm D Walkinshaw

doi:10.1016/j.chembiol.2010.10.003

CDK9 inhibitors push cancer cells over the edge

Chem Biol. 2010 Oct 29;17(10):1047-8. doi: 10.1016/j.chembiol.2010.10.003.

Authors

Matthew W Nowicki¹, Malcolm D Walkinshaw

Affiliation

¹ Centre for Translational and Chemical Biology, University of Edinburgh, King's Buildings, Mayfield Road, Edinburgh EH93JR, Scotland, UK.

PMID: 21035725
DOI: 10.1016/j.chembiol.2010.10.003

Abstract

The trouble with CDK active-site inhibitors is their tendency to have off-target effects. This is not surprising, as the ATP binding sites of most protein kinases are very similar. Wang et al. (2010) have used some clever screening approaches to identify selective CDK9 inhibitors that drive cancer cells into apoptosis.

Publication types

Comment